The business of developing drugs, vaccines, and diagnostics for neglected disease is complex. Public and private product developers must navigate tough scientific challenges, identify financing options, explore uncertain markets, and establish wide-ranging collaborations to come up with promising technologies. In recent years groups have been testing new business models that might offer a way to address these challenges.
In particular the social enterprise model, or a for-profit business that integrates a social mission into its business model, and collaborative approaches to health R&D may offer a way to expand the pool of innovators participating in global health R&D and attract fresh financing.
Join the Center for Global Health R&D Policy Assessment at the Results for Development Institute for a webinar discussion about these alternative models for global health R&D.
R4D consultant Andrew Robertson will discuss his recent report, “The Global Health Social Enterprise: An Emerging Approach to Global Health R&D” exploring the potential of social enterprise to expand the private sector’s role in developing badly needed technologies.
Bernard Munos, founder of InnoThink, will share his insights about what advantages collaborative approaches to health R&D such as open source or crowdsourcing offer for global health.
The event will conclude with a Q&A discussion with the audience.
When: December 21, 2012 from 10:30-11:30 am.
Results for Development Institute (R4D)
1100 15th Street, NW
Suite 400
Washington, DC 20005